- Kiro 7 News Ft. Dr. Steven Quay
- April 21st, 2020
Dr. Steven Quay, CEO of Atossa Therapeutics in Seattle, is preparing a drug combination called H-NAC for a clinical trial targeting COVID-19 patients on ventilators, aiming to reduce the high fatality rate associated with their usage. The drug, administered through a side port on the ventilator, forms a coating over the virus’s replication mechanisms, potentially rendering it ineffective. Quay emphasizes the need for caution in reopening the economy amidst protests, suggesting at least another two weeks to ensure safety. Plans for reopening, including prioritizing residential construction and auto sales, are being developed, with leaders urging readiness to reopen based on virus trends.
SEATTLE — The fatality rate for COVID-19 victims on ventilators has been 50% or higher.
So, at Atossa Therapeutics in Seattle, Dr. Steven Quay is getting a drug combination ready for a clinical trial in a hard-hit hospital back east.
“There’s a side port on the ventilator where you can put medication for these patients … basically they can breathe a mist while they are on the ventilator and the goal is to get them off the ventilator and once you are off the ventilator you’ll have an improved clinical course.
Quay is CEO of Seattle’s Atossa Therapeutics. He’s says he’s invented seven FDA approved drugs for other illnesses.
Called H-NAC, the drug would put a coating over the parts of the virus that help them replicate so quickly, rendering it ineffective, similar to what a vaccine does.
“We want to teach the immune system to coat the virus with antibodies, I’m coating the virus … with these two already FDA approved drugs,” he said.
